|
|
Article: Renovis Halting MS Drug After Troubles In Phase Ia.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
As word surfaced of yet another possible case of brain disease linked to the withdrawn multiple sclerosis drug Tysabri, Renovis Inc. said it is ending development of REN-850, its leukocyte-traffic inhibitor for MS, because of what it described as "unexpected pharmacokinetics" in a Phase Ia trial.
Linking REN-850 with Tysabri is "probably largely off base," said Randall Moreadith, chief medical officer of South San Francisco-based Renovis.
"We never really identified what the true target [of REN-850] was," despite great efforts, he added. Tysabri is a selective adhesion molecule inhibitor that works by binding to cell-surface ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|